Orlando Brown, Jr. speaks to reporters in front of a blue JDRF backdrop with orange and white ballons
Participant Spotlight
Read more
NFL Super Bowl Champion Orlando Brown, Jr. hosts JDRF event in Cincinnati – encourages T1D family members to get screened, help advance science
Photo courtesy of JDRF Southern & Central Ohio Chapter
During what proved to be an unforgettable celebration by the JDRF community in Cincinnati, NFL Super Bowl Champion and Bengals offensive lineman Orlando Brown, Jr. encouraged relatives of people with type 1 diabetes (T1D) to get screened by TrialNet to help advance research.
A portrait of research participant Amber wearing a gray-blue sweater and standing beside a brick wall
Participant Spotlight
Read more
Immunotherapy proven to slow T1D progression in people newly diagnosed now being tested for prevention
Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.
The text reads T1D RELAY a study for those newly diagnsoed with type 1 diabetes. Segments of light blue, dark blue and red lines run diagonally in the background.
Research Spotlight
Read more
Newly diagnosed with type 1 diabetes? Help us find out if a novel combination therapy can preserve insulin production
TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).
